

Oncimmune Holdings plc

RESULTS OF ANNUAL GENERAL MEETING

The Annual General Meeting of Oncimmune Holdings Plc was held at the offices of Peachey & Co LLP, 95 Aldwych, London, WC2B 4JF, UK on 30 November 2018 at 9:30 a.m.

All resolutions put to members were passed on a show of hands, save for resolution 1B which was conducted on a poll, the results of which are shown below. The number of votes lodged by proxy for each of the resolutions, votes lodged by proxy with discretion granted to the proxy holder, votes lodged by proxy against each of the resolutions proposed and the number of votes withheld was as follows:

Resolution Number	VOTES FOR	%	VOTES AGAINST	%	VOTES WITHHELD	Total Votes Cast	% of ISC VOTED
1A	10,149,794	100.00	0	0.00	0	10,149,794	16.47%
1B	5,637,730	56.56	4,330,323	43.44	181,741	10,149,794	16.47%
2A	10,149,794	100.00	0	0.00	0	10,149,794	16.47%
2B	10,149,794	100.00	0	0.00	0	10,149,794	16.47%
3A	10,149,794	100.00	0	0.00	0	10,149,794	16.47%
3B	10,149,794	100.00	0	0.00	0	10,149,794	16.47%
3C	10,149,794	100.00	0	0.00	0	10,149,794	16.47%
4A	9,968,053	100.00	0	0.00	181,741	10,149,794	16.47%
4B	9,968,053	100.00	0	0.00	181,741	10,149,794	16.47%
5	9,968,053	100.00	0	0.00	181,741	10,149,794	16.47%
6A	9,968,053	100.00	0	0.00	181,741	10,149,794	16.47%
6B	9,968,053	100.00	0	0.00	181,741	10,149,794	16.47%
6C	9,968,053	100.00	0	0.00	181,741	10,149,794	16.47%

The Board notes the proportion of votes cast against Resolution 1B, Directors Remuneration Report. In line with Principle 10 of the QCA Code, the Company has already entered into a dialogue with certain of the shareholders concerned and discussed the reasons for its approach to remuneration. The Directors will consider shareholder views and make relevant disclosures, if appropriate, in the 2019 annual report.

The number of the Company's shares in issue as at the date of the meeting was 61,626,327 ordinary shares of 1p.

Please note that each share carries one vote and that a 'vote withheld' is not a vote in law and will not be counted in the calculation of the proportion of the votes for and against the resolution. Any proxy appointments which gave discretion to the Chairman have been included in the votes for total.

Leaders of early cancer biomarker technology